Evaluation of Tolvaptan Effect in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Using Inverse Probability of Censoring Weighting for Long-term Extension Data.
Liver Safety of Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD): Interim Data from an EU Post-authorization Safety Study (EUPASS).
Kidney Function Decline in Patients With Autosomal Dominant Polycystic Kidney Disease: Assessment of Real-World Effectiveness of Tolvaptan.
Sibeprenlimab in patients with IgA nephropathy: a Phase 2 trial.
End-Stage Kidney Disease (ESKD), Chronic Kidney Disease (CKD) Progression and Mortality among a Racially/Ethnically Diverse Population with Primary Immunoglobulin A Nephropathy (IgAN).
Previous
Next
